Novartis: Study shows copycat works just as well as Amgen drug

ZURICH (Reuters) - Novartis's copycat version of Amgen's Neulasta worked just as well as the original drug in preventing a condition that can lead to infections among breast cancer sufferers, the Swiss company said in a statement on Monday.